BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

REGENXBIO — Lobbying — Receipts Report

LD-2 disclosure · 1st Quarter - Report

REGENXBIO

via THEGROUP DC, LLC

1st Quarter (Jan 1 - Mar 31) · 2026Posted Apr 21, 2026Filing document ↗LDA record ↗

Income$60Kfee reported

Client

Name: REGENXBIO
Description: Gene therapy biotechnology company.
Location: Maryland · United States of America

Registrant

Firm: THEGROUP DC, LLC
Description: â€‹Consulting and lobbying services.
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Health Issues
Issues related to rare disease.
LobbyistsDAVID CLEARY
TargetedExecutive Office of the President (EOP) · Health & Human Services, Dept of (HHS)

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.